Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1266071.RAtBQyawrjDU_Xv80M5khP8pl5R1wuuRim31ptvUX2qMU130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1266071.RAtBQyawrjDU_Xv80M5khP8pl5R1wuuRim31ptvUX2qMU130_assertion type Assertion NP1266071.RAtBQyawrjDU_Xv80M5khP8pl5R1wuuRim31ptvUX2qMU130_head.
- NP1266071.RAtBQyawrjDU_Xv80M5khP8pl5R1wuuRim31ptvUX2qMU130_assertion description "[All 37,992 patients were tested by immunohistochemistry (IHC); 21,642 of them were also examined for HER2 amplification with either fluorescent in situ hybridization (FISH) (11,670 patients) or chromogenic in situ hybridization (CISH) (9,972 patients); 18,262 patients had tumors other than breast or gastric cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1266071.RAtBQyawrjDU_Xv80M5khP8pl5R1wuuRim31ptvUX2qMU130_provenance.
- NP1266071.RAtBQyawrjDU_Xv80M5khP8pl5R1wuuRim31ptvUX2qMU130_assertion evidence source_evidence_literature NP1266071.RAtBQyawrjDU_Xv80M5khP8pl5R1wuuRim31ptvUX2qMU130_provenance.
- NP1266071.RAtBQyawrjDU_Xv80M5khP8pl5R1wuuRim31ptvUX2qMU130_assertion SIO_000772 25712293 NP1266071.RAtBQyawrjDU_Xv80M5khP8pl5R1wuuRim31ptvUX2qMU130_provenance.
- NP1266071.RAtBQyawrjDU_Xv80M5khP8pl5R1wuuRim31ptvUX2qMU130_assertion wasDerivedFrom befree-2016 NP1266071.RAtBQyawrjDU_Xv80M5khP8pl5R1wuuRim31ptvUX2qMU130_provenance.
- NP1266071.RAtBQyawrjDU_Xv80M5khP8pl5R1wuuRim31ptvUX2qMU130_assertion wasGeneratedBy ECO_0000203 NP1266071.RAtBQyawrjDU_Xv80M5khP8pl5R1wuuRim31ptvUX2qMU130_provenance.